Results 21 to 30 of about 1,181,836 (211)

Anti-drug antibodies and rheumatoid factor level in patients with rheumatoid arthritis using the infliximab biosimilar CT-P13 [PDF]

BMC Rheumatology, 2022
Background This study evaluated the existence of anti-drug antibodies (ADAs) before and 52 weeks after switching from intravenous infliximab (IFX) to intravenous CT-P13 in patients with rheumatoid arthritis (RA).
Hideo Sakane, Koichi Okamura, Makoto Inoue, Hiroshi Inoue, Yukio Yonemoto, Hirofumi Mitomi, Kosei Tsuchida, Takahito Suto, Tetsuya Kaneko, Hirotaka Chikuda   +9 more
doaj   +2 more sources

Clinical, Radiological and Pharmacokinetic Data of CT-P13 Subcutaneous in Individuals with Fistulizing Anoperineal Crohn's Disease. [PDF]

Dig Dis Sci
The aim of this study was to evaluate the clinico-radiological remission rate in patients with fistulizing anoperineal lesions of Crohn’s disease treated with CT-P13 SC, as well as pharmacokinetic data and treatment persistence rate.
Fathallah N, Draullette M, Kirchgesner J, Paul S, Roblin X, Bourrier A, Haouari MA, Chambenois E, Morisset S, Seksik P, de Parades V.   +10 more
europepmc   +2 more sources

Safety, efficacy, and drug survival of the infliximab biosimilar CT-P13 in post-marketing surveillance of Japanese patients with psoriasis. [PDF]

J Dermatol, 2022
Based on extrapolation of similar clinical outcomes in rheumatoid arthritis to the originator infliximab (IFX) in randomized clinical trials, the first biosimilar antibody CT‐P13 was approved for the treatment of psoriasis.
Morita A, Nishikawa K, Yamada F, Yamanaka K, Nakajima H, Ohtsuki M.   +5 more
europepmc   +2 more sources

Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials [PDF]

Arthritis Research & Therapy, 2021
Background A subcutaneous (SC) formulation of infliximab biosimilar CT-P13 is approved in Europe for the treatment of adult patients with rheumatoid arthritis (RA). It may offer improved efficacy versus intravenous (IV) infliximab formulations. Methods A
Bernard Combe, Yannick Allanore, Rieke Alten, Roberto Caporali, Patrick Durez, Florenzo Iannone, Michael T. Nurmohamed, Mondher Toumi, Sang Joon Lee, Taek Sang Kwon, Jiwon Noh, Gahee Park, Dae Hyun Yoo   +12 more
doaj   +2 more sources

Real-World Effectiveness and Safety of Infliximab Biosimilar CT-P13 for Rheumatic Diseases: A National Observational Cohort Study (ReFLECT). [PDF]

Adv Ther
ReFLECT was a French multicenter, observational cohort study evaluating the effectiveness and safety of CT-P13, an infliximab (IFX) biosimilar, in a real-world setting. Here, we describe the results for patients with rheumatic disease.
Marotte H, Cantagrel A, Coury F, Schaeverbeke T, Assing M, Kessouri M, Brault Y, Fautrel B.   +7 more
europepmc   +2 more sources

Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY). [PDF]

J Crohns Colitis
Background and Aims In the LIBERTY phase 3 studies in Crohn’s disease (CD) or ulcerative colitis (UC), maintenance CT-P13 subcutaneous (SC) 120 mg was more effective than placebo after 1 year.
Colombel JF, Sandborn WJ, Schreiber S, Danese S, Kłopocka M, Kierkuś J, Kulynych R, Gonciarz M, Sołtysiak A, Smoliński P, Srećković S, Valuyskikh E, Lahat A, Horyński M, Gasbarrini A, Osipenko M, Borzan V, Kowalski M, Saenko D, Sardinov R, Lee SJ, Kim S, Bae Y, Lee S, Lee S, Lee JH, Kim JM, Park G, Lee J, Lee J, Ryu JY, Sands BE, Hanauer SB.   +32 more
europepmc   +2 more sources

Immunogenicity of the biosimilar CT-P13 infliximab or the original infliximab in Iraqi patients with Ankylosing spondylitis does not correlate with their demographic characteristics [PDF]

مجلة كلية الطب, 2023
Background: Ankylosing spondylitis is a rare disease affecting people with hereditary factors. Its treatment includes life style modification and use of drugs such as the biologic agent infliximab or its biosimilar, CT-P13 infliximab.
Mohammed M. Kamil, Mohammed Abdul- Hassan Jabarah, Nizar A.l. Jasim   +2 more
doaj   +3 more sources

Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID‐19) pandemic: A case series [PDF]

Clinical Case Reports, 2022
The COVID‐19 pandemic emphasized the utility of subcutaneous (SC) biologics for pressured healthcare systems. The first SC form of infliximab, CT‐P13 SC, provided safe and effective treatment for ankylosing spondylitis in our case series, with increased ...
Sooraj Vijayan, Kyungmin Hwangbo, Nick Barkham   +2 more
doaj   +2 more sources

Switching From Reference Infliximab to Biosimilar CT-P13 Did Not Change Quality of Life in Stable Inflammatory Bowel Disease Patients. [PDF]

Crohns Colitis 360, 2022
Background: Quality of life (QoL) data for patients with inflammatory bowel disease switched from the reference infliximab to biosimilar CT-P13 is lacking.
Pierik MJ, van der Meulen AE, Van der Linde K, Lutgens M, Kuijvenhoven JP, Akol H, Klompmaker IJ, Sikkens MSG, van Megen YJB, Stoop CM, Bloemsaat-Minekus JPJ, Dijkstra G.   +11 more
europepmc   +3 more sources

Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease [PDF]

Inflammatory Bowel Diseases, 2021
BACKGROUND: Patients suffering from inflammatory bowel diseases (IBD) and treated with originator infliximab are increasingly being switched to biosimilars. Some patients, however, are "reverse switched" to treatment with the originator.
Dijkstra, Gerard, Fidder, Herma H, Gilissen, Lennard P L, Hoentjen, Frank, Lutgens, Maurice W M D, Mahmmod, Nofel, Mahmmod, Shaden, Oldenburg, Bas, Schultheiss, Johannes P D, Smits, Lisa J T, Tan, Adriaan C I T L, van Bodegraven, Ad A, van der Meulen-de Jong, Andrea E   +12 more
core   +2 more sources